Vonoprazan: MarKed Competition for PPIs?
Dig Dis Sci
.
2016 Jul;61(7):1783-4.
doi: 10.1007/s10620-016-4164-8.
Authors
David R Scott
1
2
,
Elizabeth A Marcus
3
4
,
George Sachs
5
6
4
Affiliations
1
Department of Physiology, DGSOM at UCLA, Los Angeles, CA, USA.
[email protected]
.
2
VA GLAHS, 11301 Wilshire Blvd., Bldg. 113, Rm. 324, Los Angeles, CA, USA.
[email protected]
.
3
Department of Pediatrics, DGSOM at UCLA, Los Angeles, CA, USA.
4
VA GLAHS, 11301 Wilshire Blvd., Bldg. 113, Rm. 324, Los Angeles, CA, USA.
5
Department of Physiology, DGSOM at UCLA, Los Angeles, CA, USA.
6
Department of Medicine, DGSOM at UCLA, Los Angeles, CA, USA.
PMID:
27074922
PMCID:
PMC4920708
DOI:
10.1007/s10620-016-4164-8
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Proton Pump Inhibitors*
Pyrroles
Sulfonamides*
Substances
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
Proton Pump Inhibitors
Pyrroles
Sulfonamides
Grants and funding
I01 BX001006/BX/BLRD VA/United States
K08 DK100661/DK/NIDDK NIH HHS/United States
R01 DK105156/DK/NIDDK NIH HHS/United States